Pulse Biosciences (NASDAQ:PLSE) Upgraded to Strong-Buy at BTIG Research

Pulse Biosciences (NASDAQ:PLSE) was upgraded by research analysts at BTIG Research to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

Several other research firms also recently commented on PLSE. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Freedom Capital raised shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Finally, Mizuho set a $45.00 price target on Pulse Biosciences in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $50.20.

Pulse Biosciences Stock Performance

Shares of Pulse Biosciences stock opened at $51.98 on Wednesday. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90. The stock’s 50-day simple moving average is $44.45 and its 200 day simple moving average is $30.99. The stock has a market capitalization of $3.68 billion, a P/E ratio of -44.05 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Equities research analysts forecast that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Insider Activity

In other news, COO Liane Teplitsky purchased 1,001 shares of the stock in a transaction dated Tuesday, September 1st. The shares were purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This represents a 32.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have bought 4,095 shares of company stock valued at $199,931 over the last quarter. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds have recently bought and sold shares of PLSE. BlackRock Inc. bought a new stake in Pulse Biosciences during the 2nd quarter worth approximately $40,672,000. Bank of America Corp DE bought a new position in Pulse Biosciences in the 2nd quarter valued at $40,115,000. Panoramic Capital LLC purchased a new position in shares of Pulse Biosciences during the 2nd quarter valued at $2,719,000. Bank of New York Mellon Corp purchased a new position in shares of Pulse Biosciences during the 2nd quarter valued at $1,196,000. Finally, Formula Growth Ltd. purchased a new position in shares of Pulse Biosciences during the 2nd quarter valued at $832,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.